Bipartisan Bill Would Allow Research on Schedule I Breakthrough Therapy Drugs

Newly proposed bipartisan legislation would require the Drug Enforcement Administration (DEA) to reclassify psilocybin and MDMA (“Ecstasy”) from Schedule I to Schedule II drugs, relaxing some of the federal laws that have so far complicated research on strictly controlled psychoactive drugs.
Source: Drug Industry Daily